The goal of this proposal is to understand the molecular mechanism that governs conventional T (Tcon) cell resistance to regulatory T cell (Treg)-mediated suppression and identify potential molecular targets for use in immunotherapy. Research over the past decade has demonstrated that Treg cells are a crucial component for a healthy immune system. Once activated through their T cell receptor (TCR), Treg cells can suppress a wide range of immune cells. It is becoming evident that in many autoimmune diseases, Treg cells remain functional, yet fail to control Tcon cells. At the same time, Treg cell hinder anti-tumor immunity by creating a suppressive tumor microenvironment. Therefore, it is important to understand what determines if a Treg cell is able to successfully suppress its target, and how this plays a role in both autoimmune disease and cancer. My research focuses on the Src homology 2 domain- containing protein tyrosine phosphatase 1 (SHP-1), a well-characterized negative regulator of TCR-mediated signaling. Using three different genetic models of SHP-1 deficiency, I have recently found that SHP-1 regulates the susceptibility of Tcon cells to suppression, such that SHP-1-deficient Tcon cells display increased resistance to wt Treg-mediated suppression. In preliminary data, I have shown that Tcon cells derived from motheaten mice, which lack SHP-1 expression in all hematopoietic cells, are resistant to Treg-mediated suppression. I also observed a comparable resistance in Tcon cells from two different mouse models, carrying a T cell specific deletion of SHP-1, indicating that the SHP-1-dependent resistance to suppression is a T cell-intrinsic effect. Moreover, treatment of mice with sodium stibogluconate (SSG), a pharmacological SHP-1 inhibitor, also rendered Tcon cells resistant to Treg-mediated suppression, further reinforcing the role of SHP-1 in regulating Tcon cell susceptibility to Treg suppression. Interestingly, SSG is in phase I clinical trials for solid tumo immunotherapy, yet its anti-tumor mechanism remains unclear. The proposed study will shed light on how SSG might be augmenting Tcon cells' ability to resist Treg-mediated suppression and mount a more effective anti-tumor response. This proposal will address the role of SHP-1 in CD4+ and CD8+ T cell susceptibility to Treg mediated suppression both at the level of intracellular signaling pathways as well as in vivo in models of autoimmune disease, inflammation, and anti-tumor immunity. From these studies, I will identify possible molecular drug targets, the modulation of which would either induce Tcon cell susceptibility to Treg-suppression for treatment of autoimmune disease, or allow Tcon cells to resist Treg suppression for treatment of cancer.

Public Health Relevance

Autoimmune disease and cancer, combined, affect a large portion of the population and can be viewed as opposites in terms of the immune response. On the one hand, autoimmune disease represents an over-active, inappropriate immune response, while cancer is the result of and perpetuates an under-active, impaired immune response. The proposed work aims to better understand what regulates the balance between a strong effector immune response versus suppression of that response, and to identify targets for therapeutic intervention.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Predoctoral Individual National Research Service Award (F31)
Project #
5F31AI110146-03
Application #
9081482
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Adger-Johnson, Diane S
Project Start
2014-07-01
Project End
2017-06-30
Budget Start
2016-07-01
Budget End
2017-06-30
Support Year
3
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Virginia
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Mercadante, Emily R; Lorenz, Ulrike M (2017) T Cells Deficient in the Tyrosine Phosphatase SHP-1 Resist Suppression by Regulatory T Cells. J Immunol 199:129-137